Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
01.10. | Sera Prognostics Appoints Tiffany Inglis As CMO | - | RTTNews | ||
01.10. | Sera Prognostics appoints Dr. Tiffany Inglis as chief medical officer | 1 | Investing.com | ||
01.10. | Sera Prognostics, Inc.: Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer | 66 | PR Newswire | SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy... ► Artikel lesen | |
05.09. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
05.09. | Sera Prognostics forciert Kommerzialisierung des PreTRM-Tests | 1 | Investing.com Deutsch | ||
21.08. | Sera Prognostics übertrifft Gewinnprognose - Aktie steigt trotz schwachem Umsatz | 3 | Investing.com Deutsch | ||
07.08. | Sera Prognostics outlines European expansion and new commercial hires while targeting PreTRM Test reimbursement pilots | 1 | Seeking Alpha | ||
06.08. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
06.08. | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2025 Financial Results | 67 | PR Newswire | SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
05.06. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
08.05. | Sera Prognostics names Lee Anderson as new CCO | 1 | Investing.com | ||
08.05. | Sera Prognostics ernennt Lee Anderson zum neuen CCO | 9 | Investing.com Deutsch | ||
08.05. | Sera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial Officer | 208 | PR Newswire | Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company®... ► Artikel lesen | |
07.05. | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
07.05. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
07.05. | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial Results | 305 | PR Newswire | SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
19.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2024 Financial Results | 212 | PR Newswire | SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
06.11.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2024 Financial Results | 155 | PR Newswire | SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NANOREPRO | 1,520 | -7,88 % | Original-Research: NanoRepro AG (von GBC AG): Kaufen | Original-Research: NanoRepro AG - von GBC AG
09.10.2025 / 12:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw.... ► Artikel lesen | |
OCUGEN | 1,260 | -6,63 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
VIKING THERAPEUTICS | 26,705 | -6,02 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity | Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735
Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated... ► Artikel lesen | |
COSCIENS BIOPHARMA | 2,160 | 0,00 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
BIOCRYST PHARMACEUTICALS | 6,094 | +1,20 % | BioCryst's $700M Astria Acquisition Gives It a Shot to Beat Larger Rivals in Rare Disease HAE | ||
VAXART | 0,265 | -24,06 % | Vaxart, Inc.: Vaxart Announces Withdrawal of Reverse Stock Split Proposal | SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
IBIO | 1,240 | +28,50 % | Oppenheimer initiates iBio stock with Outperform rating on obesity drug potential | ||
REDHILL BIOPHARMA | 1,760 | -0,56 % | RedHill Biopharma Ltd.: RedHill's Talicia Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal | Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business
U.S.... ► Artikel lesen | |
ARBUTUS BIOPHARMA | 3,800 | -1,76 % | Arbutus Biopharma Corporation: Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation... ► Artikel lesen | |
CARDIFF ONCOLOGY | 1,892 | -1,36 % | Cardiff Oncology nach Daten-Dip: Jetzt kaufen? | Cardiff Oncology legt seine lang erwarteten Krebs-Daten vor und der Aktienkurs fährt Achterbahn: Bietet sich für Anleger ein neues Trading-Fenster, oder lässt man jetzt besser die Finger von dem Titel?... ► Artikel lesen | |
MANNKIND | 4,827 | +1,51 % | MannKind: Stiller Gewinner im Kampf um die Lunge? | Nach einer Reihe operativer Fortschritte und der Übernahme von scPharmaceuticals richtet sich bei Aktionären der MannKind Corporation der Blick in die Zukunft. Die fundamentale Basis scheint geschaffen.... ► Artikel lesen | |
ALDEYRA | 4,460 | -6,01 % | Jefferies erhöht Kursziel für Aldeyra Therapeutics nach FDA-Annahme auf 7 US-Dollar | ||
TRAWS PHARMA | 2,695 | -9,56 % | Traws Pharma stattet Führungskräfte mit Aktienoptionen aus | ||
CARISMA THERAPEUTICS INC | 0,025 | -1,20 % | XFRA W2J: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |